<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1201">
  <stage>Registered</stage>
  <submitdate>14/06/2006</submitdate>
  <approvaldate>14/06/2006</approvaldate>
  <nctid>NCT00336986</nctid>
  <trial_identification>
    <studytitle>Efficacy Study of IL-21 to Treat Metastatic Melanoma</studytitle>
    <scientifictitle>An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NN028-1614</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer</healthcondition>
    <healthcondition>Malignant Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - recombinant interleukin-21

Treatment: drugs: recombinant interleukin-21


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tumor size assessed according to international criteria</outcome>
      <timepoint>After 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum levels of antibodies against recombinant human IL-21.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Markers of immunomodulation in blood.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety evaluation.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed surgically incurable metastatic melanoma

          -  Patients must have measurable disease

          -  ECOG performance status of 0 or 1

          -  Expected life expectancy at least 4 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of and signs/symptoms of uncontrolled brain metastases or edema.

          -  Previous treatment with chemotherapy or any biological anti-cancer drug (prior
             adjuvant therapy with interferon-alpha is permitted as long as treatment was completed
             at least six months prior to study entry.)

          -  Radiotherapy: Radiation therapy within 4 weeks prior to entering the study.

          -  Receipt of any investigational drug for treatment of metastatic melanoma prior to this
             trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>54</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Novo Nordisk Investigational Site - Box Hill</hospital>
    <hospital>Novo Nordisk Investigational Site - East Melbourne</hospital>
    <hospital>Novo Nordisk Investigational Site - Heidelberg</hospital>
    <hospital>Novo Nordisk Investigational Site - Malvern</hospital>
    <hospital>Novo Nordisk Investigational Site - Nedlands</hospital>
    <hospital>Novo Nordisk Investigational Site - Parkville</hospital>
    <hospital>Novo Nordisk Investigational Site - Westmead</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>2145 - Westmead</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At
      least 14 to a maximum of 40 patients, who have not previously received treatment for their
      stage IV disease, will be treated for 6 weeks. IL-21 will be administered intravenously.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00336986</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR; 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>